|
Post by awesomo on Apr 30, 2019 17:28:35 GMT -5
even with a 1:10 reverse split Tandem Diabetes had a 1:10 reverse split? Ouch. Yeah, in 2017, about half a year later than MannKind's 1:5 RS. Except look at what Tandem has done since that, and now look at us...
|
|
|
Post by mnkdfann on Apr 30, 2019 17:35:58 GMT -5
even with a 1:10 reverse split Tandem Diabetes had a 1:10 reverse split? Ouch. How do you figure 'ouch'? It seems it did a reverse split right. Tandem reorganised its capital structure, and it paid off like crazy. Shares have exploded up in value since the split occurred in October of 2017.
|
|
|
Post by prcgorman2 on May 1, 2019 8:57:23 GMT -5
Good for Tandem. I do think many of the disgruntled Mannkind posters would be much happier if they spent more time on the Tandem board and less over here on the Mannkind board.
|
|
|
Post by cretin11 on May 1, 2019 17:01:35 GMT -5
I think most of us would be pretty bitter if we were on the Tandem board, being reminded how much $$ they're making compared to us. I'd rather be among the disgruntled here, at least hoping we can all celebrate one day.
|
|
|
Post by mytakeonit on May 1, 2019 19:33:09 GMT -5
And ... on the Tandem board they are saying ... awww, I wish I had bought MNKD at the end of 2018 when it was $1.08 !!! Today it is at $1.47 and up 36% !!!
Fast forward 5 years ... on the Tandem board they are saying ... awww, I wish I had bought MNKD at the end of 2018 when it was $1.08 !!! Today it is at $147 and up 13611% !!!
But, that's mytakeonit
|
|
|
Post by uvula on May 1, 2019 19:56:01 GMT -5
I'm confused. Some people here keep saying the insulin pump is dead because of afrezza. Better tell the Tandem stockholders to sell while they can.
|
|
|
Post by agedhippie on May 1, 2019 21:58:15 GMT -5
I'm confused. Some people here keep saying the insulin pump is dead because of afrezza. Better tell the Tandem stockholders to sell while they can. You are right, insulin pumps are not going anywhere. They will morph into APs and that's where I expect the majority of the Type 1 market to go. I don't know why people get so bent out of shape over this. Type 1 diabetics are around 20% of the diabetic in the US, and 60% of those are using pumps. That leaves 88% of the market for Afrezza to chase - I would have thought that was enough!
|
|
johny
Researcher
Posts: 87
|
Post by johny on May 1, 2019 23:27:53 GMT -5
I'm confused. Some people here keep saying the insulin pump is dead because of afrezza. Better tell the Tandem stockholders to sell while they can. You are right, insulin pumps are not going anywhere. They will morph into APs and that's where I expect the majority of the Type 1 market to go. I don't know why people get so bent out of shape over this. Type 1 diabetics are around 20% of the diabetic in the US, and 60% of those are using pumps. That leaves 88% of the market for Afrezza to chase - I would have thought that was enough! Somewhere between 1.5 and 3 million Americans are living with Type 1 diabetes. (https://wbur.fm/2IWbW4E) About 10% of all diabetics are T1D. Couldn't find 20% anywhere. (https://bit.ly/2FrTiks) 07 March 2019 "It is estimated that 400,000 patients with T1D in the U.S. are using insulin pumps." (https://bit.ly/2GWM0nh) 2018 Aug ADA reported 1.5 million T1D in 2015. Going off of 2 million T1D, 20% use an insulin pump, couldn't find 60% anywhere. "A recent report from the T1D Exchange Clinic Registry indicated that 60% of the 16,061 adult and pediatric patients with T1D in that cohort used an insulin pump." (http://care.diabetesjournals.org/content/41/8/1579) ------------------------------------------------------------------------------------------------------------------------------------------------- Numbers are always changing, but you'd think ADA would be more on top of their diabetic statistics. Do the numbers above give Afrezza more market share? It's never enough.
|
|
|
Post by sweedee79 on May 2, 2019 7:47:39 GMT -5
I'm confused. Some people here keep saying the insulin pump is dead because of afrezza. Better tell the Tandem stockholders to sell while they can. Maybe you should sell your MNKD shares and buy Tandem? Don't recall anyone saying the insulin pump was dead because of Afrezza. That's a little bit of an exaggeration.... Ya think?
|
|
|
Post by uvula on May 2, 2019 9:03:24 GMT -5
I'm confused. Some people here keep saying the insulin pump is dead because of afrezza. Better tell the Tandem stockholders to sell while they can. Maybe you should sell your MNKD shares and buy Tandem? Don't recall anyone saying the insulin pump was dead because of Afrezza. That's a little bit of an exaggeration.... Ya think? I'm not going to search through old posts but it is not an exaggeration at all. Maybe no one said the pump is dead but several of us have claimed that afrezza will kill the pump, and people even claimed Al Mann said this also.
|
|
|
Post by prcgorman2 on May 2, 2019 9:17:29 GMT -5
The story isn’t over is it?
|
|
|
Post by mango on May 2, 2019 9:20:01 GMT -5
Maybe you should sell your MNKD shares and buy Tandem? Don't recall anyone saying the insulin pump was dead because of Afrezza. That's a little bit of an exaggeration.... Ya think? I'm not going to search through old posts but it is not an exaggeration at all. Maybe no one said the pump is dead but several of us have claimed that afrezza will kill the pump, and people even claimed Al Mann said this also. I know he mentioned something like that in his Johns Hopkins speech. Said CGMs & might have said pumps too I forget. It's a good video, might watch it later today.
|
|